Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

to Evaluate SCT510 Compared to Avasitin Respectively Combined Paclitaxel and Carboplatin First-line Treatment of Locally Advanced and Metastatic or Recurrent Squamous Cell Non-small Cell Lung Cancer Efficacy and Safety

NCT03792074 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT03792074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03792074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
to Evaluate SCT510 Compared to Avasitin Respectively Combined Paclitaxel and Carboplatin First-line Treatment of Locally Advanced and Metastatic or Recurrent Squamous Cell Non-small Cell Lung Cancer Efficacy and Safety
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
February 28, 2019
Completion date
January 31, 2022
Enrollment
560 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous cell non-small cell lung cancer